Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (NCT02969837), a na phase 2 study. The primary outcome is Number of Participants With Stringent Complete Response (sCR).

2. Clinical Question

3. Trial Design

This was a phase 2, open-label, single-arm study of initial treatment with elotuzumab, carfilzomib, lenalidomide and low-dose dexamethasone in newly diagnosed multiple myeloma requiring systemic chemotherapy. The registry lists the sponsor as the University of Chicago and describes the study as multicenter. It reports an enrollment of 46 and a completed status. The listed study start was 2017-07-10, and the primary completion date was 2021-10-11.

Because there was one treatment group and no masking, the design can describe outcomes observed among participants who received the regimen, but it cannot directly compare those outcomes with a concurrent control. The allocation field is listed as not applicable. There is no like-for-like control group in the record, and comparisons with people treated in other settings would require evidence and methods not reported.

The primary outcome entry is the number of participants with sCR. The brief summary frames the primary endpoint as the rate of sCR and/or MRD-negativity (10-5) after C8 Elo-KRd. The outcome description lists landmark evaluations after cycles 4, 8, 12, 18 and 24, and also states these as 4, 8, 12, 18 and 24 months. Secondary outcomes include safety, response rate, MRD status, progression-free survival and overall survival; the registry also lists duration of response and median survival outcomes. Outcome names alone do not establish their observed values. The registry record does not report the primary response count or an analysis comparing outcomes with another treatment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: One censored because of autologous stem cell transplant cycle 8 without progression

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Stringent Complete Response (sCR), measured over Landmark evaluations were performed after cycles 4, 8, 12, 18 and 24 (that is, 4, 8, 12, 18 and 24 months).

The primary outcome is named as the number of participants with stringent complete response (sCR), a binary response outcome: a participant either meets the stated response criteria at an assessment or does not. The registry describes response according to International Myeloma Working Group criteria. It defines sCR as complete response plus a normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or 2 - 4 color flow cytometry. Complete response includes negative immunofixation on serum and urine, disappearance of soft tissue plasmacytomas, and < 5% plasma cells in bone marrow. In subjects with only FLC disease, a normal FLC ratio of 0.26-1.65 is required.

A stringent response definition aims to classify depth of response using specified laboratory and marrow findings. As a general statistical point, a count can describe how many participants met a criterion, while a rate also needs a clearly defined denominator and assessment time. The record lists landmark evaluations after cycles 4, 8, 12, 18 and 24, stated as 4, 8, 12, 18 and 24 months. However, the brief summary describes the primary endpoint as sCR and/or MRD-negativity (10-5) after C8, whereas the primary outcome entry names sCR alone. The registry record does not report the observed endpoint value, so the frequency and precision of response cannot be assessed from the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a single-arm design estimate?

In a single-arm study, participants receive the study regimen and outcomes are described within that group. The design can estimate a response proportion or summarize observed safety events if the underlying outcome data and analysis are reported. Here, the registry identifies one group and an enrollment of 46, but does not give the primary response count or its rate. Therefore, no response estimate or interval can be interpreted from the registry record.

Without a concurrent comparator, there is no randomized between-group contrast. A general statistical distinction is that a within-group outcome answers “what was observed among these participants?” while a comparative effect asks how outcomes differ between treatment strategies. The latter needs comparison data and suitable design and analysis. Single-arm observations can be useful for describing a cohort, but they cannot by themselves distinguish the regimen’s effect from other influences on outcomes.

How should a binary response endpoint be understood?

sCR is a categorical outcome defined by clinical and laboratory criteria. For a binary endpoint, participants are classified according to whether they meet the definition at a specified assessment. A count gives the number meeting it; a proportion additionally relates that count to an analysis denominator. A confidence interval, when reported, describes statistical uncertainty around an estimate under the analysis assumptions. It does not resolve limitations in the design, endpoint definition, or representativeness of the participants.

The registry names the primary outcome as a participant count with sCR and gives assessment landmarks after cycles 4, 8, 12, 18 and 24, stated as 4, 8, 12, 18 and 24 months. The brief summary instead describes sCR and/or MRD-negativity (10-5) after C8. Those formulations need not identify the same binary outcome. The record does not explain how the two formulations were reconciled, and no primary result is reported. It is therefore not possible to know the analyzed endpoint’s observed frequency or estimate its uncertainty.

What does censoring mean in this record?

The primary outcome population note says one participant was censored because of autologous stem cell transplant at cycle 8 without progression. In general, censoring means that a participant’s follow-up for a particular outcome is incomplete or ends before the event status can be fully observed under the analysis definition. Its implications depend on the endpoint, timing, and analysis rules. A person censored in a time-to-event analysis may contribute information up to the censoring time; a binary response analysis may handle an unavailable assessment differently. The registry record does not say which analysis population or missing-outcome rule was used for the primary endpoint, so the effect of this censoring on the response result cannot be determined.

How should time-to-event outcomes be read?

The secondary outcomes include median progression-free survival, median overall survival and duration of response. These are time-to-event outcomes: the relevant information includes both whether an event occurred and when it occurred, with participants who have not had an event potentially contributing follow-up up to their last known assessment. Median survival is a summary of the event-time distribution, not an average treatment effect and not a comparison with another regimen. The registry record does not report these outcome values, event counts for these endpoints, confidence intervals, or model-based comparisons.

In general, time-to-event estimates depend on the event definition, censoring rules, follow-up duration and assumptions of the analysis. For comparisons across groups, methods may also require assumptions about how relative event rates behave over time. Those details are not reported in the registry record. Without estimates and methods, the outcome titles alone cannot show the distribution of survival times or the precision of any median.

What is the role of planning calculations?

A planning illustration based on an observed effect is not an analysis of the trial’s observed evidence. The record’s stated illustration assumptions use a two-sided significance level of 0.05, equal allocation between two arms and a normal approximation, with the effect to detect set as a stated fraction of the observed effect. For time-to-event outcomes, the illustration is based on total events; for other outcomes, it is expressed as participants per arm. These are planning conventions, not proof that a study has adequate evidence, and not “observed power.” The record does not report the trial’s own sample-size justification. In particular, planning calculations for a two-arm comparison do not turn this single-arm study into a comparative trial.

More generally, a sample-size illustration depends on its assumptions about the target effect, error rate, allocation and statistical model. Changing those assumptions changes the planning result. A calculation anchored to an observed effect is especially not an independent confirmation of that effect. Such an illustration can help frame future study planning, but it should not be read as a result from this study or as evidence that the observed endpoint was statistically significant.

Why does dispersion matter?

General statistical note: over-dispersion occurs when variability in count data exceeds what a simple model assumes. If ignored, standard errors and confidence intervals can be too small, making results appear more precise than warranted. A count of participants with an event is not automatically over-dispersed; the appropriate model depends on how the outcome was collected and analyzed. The registry record does not report a model for the primary count outcome, dispersion estimates, or inferential analysis, so no claim about over-dispersion or model adequacy can be made.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Elo-KRd Regimen")
n      <- c(45)
events <- c(17)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Elo-KRd Regimen  45  17  37.8  23.8  53.5  25.1  52.4  25.1  52.5

11. Multiplicity, Missing Data and Analysis Populations

The registry lists several outcome domains: stringent complete response, safety, response rate, MRD status, progression-free survival, overall survival and duration of response. When a study tests or emphasizes multiple endpoints, the chance of at least one apparently notable result can increase unless the analysis plan addresses multiplicity. This is a general statistical concern, not evidence that a particular adjustment was or was not used in this study. The registry record does not report a multiplicity strategy, hierarchy among secondary outcomes, or allocation of statistical error across outcomes.

The primary outcome entry and brief summary describe the primary endpoint differently: the former names the number of participants with sCR, while the latter describes sCR and/or MRD-negativity (10-5) after C8. That distinction matters for multiplicity as well as interpretation, because a composite endpoint and its components can create different analysis questions. The registry record does not report a protocol-level explanation of the distinction, a prespecified analysis plan, or separate results for those measures.

Missing-data and analysis-population details are also limited. The primary outcome population note identifies one participant censored because of autologous stem cell transplant at cycle 8 without progression. The record does not report the primary endpoint denominator, how that participant was treated in the response analysis, the number of participants with unevaluable assessments, or rules for missing outcome data. It also does not identify an intention-to-treat, per-protocol or other analysis population for the reported outcomes. No inferential analyses are listed. Thus, the record does not allow assessment of how exclusions, censoring or missing assessments may have affected the endpoint estimates.

The registry record does not report interim analyses, stopping rules or a complete statistical analysis plan. Those procedures should not be inferred from the phase or study design. The absence of these details limits the ability to evaluate whether outcome selection, missing-data handling and multiplicity were prespecified.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: lung infection (10.9%), febrile neutropenia (4.3%), fever (4.3%), acute kidney injury (2.2%), atrial fibrillation (2.2%).

The registry lists 46 participants at risk for both serious and other adverse events. It reports 18 participants affected by serious adverse events and 42 affected by other adverse events. These are participant counts, not numbers of individual event episodes, and the record does not provide exposure-adjusted rates in the information. The registry also reports 8 deaths. The record does not give causes of death or state that the deaths were attributed to treatment, so the count should not be read as a treatment-related death count.

The listed serious adverse event terms and percentages are lung infection, 10.9%; febrile neutropenia, 4.3%; fever, 4.3%; acute kidney injury, 2.2%; atrial fibrillation, 2.2%; and bronchial infection, 2.2%. These figures indicate the listed terms and their reported percentages, but the registry entry does not explain whether a participant could contribute to more than one term or provide event-level timing and duration. The percentages should therefore be read as registry-reported values, not recalculated or treated as mutually exclusive categories.

As a general statistical point, safety counts in a single treated group describe what was recorded in that group. Without a concurrent comparator, they do not estimate excess risk attributable to the regimen. Differences in follow-up, exposure and event ascertainment can also affect comparisons between studies. The registry record does not report a comparative safety analysis or detailed attribution results.

13. What the Result Does, and Does Not, Mean

The study record describes a completed phase 2 evaluation of a four-drug regimen in newly diagnosed multiple myeloma requiring systemic chemotherapy. It documents a single-group, open-label design, an enrollment of 46 and a response-assessment schedule. It also reports selected adverse-event counts and serious adverse event terms. These details help a reader understand the type of evidence collected and the context in which safety events were recorded.

The record does not report the primary response count or rate, nor does it provide an interval or test result for that endpoint. The central response question therefore remains numerically unanswered in the registry record. A description of how sCR is defined cannot substitute for an observed response estimate. Likewise, the brief summary’s mention of sCR and/or MRD-negativity (10-5) after C8 does not establish the observed result for either measure.

Even if a response estimate were available, this single-arm design would describe outcomes in participants receiving the regimen, not establish a comparative effect against another treatment. There is no randomized control group in the record. The listed safety counts similarly describe observed events, but do not show how event frequency differs from a comparator or identify which events were caused by treatment.

These boundaries do not make the registry information uninformative. Study design, endpoint definitions, assessment timing and event counts are relevant for understanding what was planned and reported. They do, however, set limits on what can be concluded. The available record supports a description of the study and selected safety information; it does not support a conclusion about the magnitude, precision or comparative meaning of the primary efficacy outcome.

14. Why This Trial Matters Statistically

This trial is statistically informative as an example of the gap between a clearly named endpoint and a result that can actually be interpreted. The registry specifies stringent complete response criteria and landmark assessments, yet does not report the primary response count or rate. For clinical research readers, this distinction is essential: a protocol description tells what is intended to be measured, while an outcome estimate tells what was observed in the analyzed participants.

The record also illustrates why endpoint wording matters. The primary outcome entry identifies sCR alone, while the brief summary describes sCR and/or MRD-negativity (10-5) after C8. A composite and a single component answer different questions and can yield different counts. Without clarification and separate outcome values, readers cannot determine the exact primary analysis or its result from the registry record.

The single-arm design highlights a second statistical issue: a response description is not the same as a comparative treatment effect. Without a concurrent control, the observed experience of the treated group cannot establish how outcomes would differ under another strategy. This distinction remains important even when a study is phase 2 and reports detailed outcome criteria.

Finally, the safety entry shows why counts need context. Counts of participants affected and listed event percentages are useful descriptions, but interpretation also depends on exposure, follow-up, attribution and comparison. Those details are not fully reported in the registry record. The study therefore offers a useful case for reading endpoint definitions, study design and safety summaries together, while keeping conclusions within the limits of what is actually reported.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation for interpreting efficacy is that the registry record does not report the primary response result. It gives the endpoint name and response criteria but no observed participant count, rate, confidence interval or inferential analysis. The record also presents two formulations of the primary endpoint: sCR in the primary outcome entry, and sCR and/or MRD-negativity (10-5) after C8 in the brief summary. It does not explain how these formulations relate.

The single-arm design has no concurrent control group, so it cannot support a randomized comparison. The study is open-label and does not list masking. The registry record does not report methods that would allow evaluation of potential assessment bias or the impact of unmasked treatment on outcome ascertainment.

Outcome follow-up and analysis details are incomplete in the information. The record lists landmark evaluations after cycles 4, 8, 12, 18 and 24, stated as 4, 8, 12, 18 and 24 months, but does not provide endpoint results at those landmarks. It notes one participant censored because of autologous stem cell transplant at cycle 8 without progression, without reporting how censoring or other unavailable assessments were handled in the primary analysis. Analysis populations and missing-data rules are not reported in the registry record.

For safety, the record gives counts and selected event terms but not detailed timing, exposure-adjusted rates, causes of death or attribution. The registry record also does not report the trial’s sample-size justification, interim analyses, multiplicity approach or full statistical plan. These limitations restrict assessment of precision, potential bias and the interpretation of both response and safety findings.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma — NCT02969837.
• Registry record last updated 2026-01-16; status last verified 2025-12.
• Results first posted 2025-09-10.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes NCT02969837 as a completed, open-label, single-arm phase 2 study sponsored by the University of Chicago. It evaluated initial treatment with elotuzumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma requiring systemic chemotherapy. The record reports 46 enrolled participants, a study start date of 2017-07-10 and a primary completion date of 2021-10-11.

The primary outcome is listed as the number of participants with sCR, with response assessments at several cycle landmarks. The brief summary also refers to sCR and/or MRD-negativity (10-5) after C8. The primary result and inferential analyses are not reported in the registry record. Safety information includes counts of participants with serious and other adverse events, deaths, and selected serious adverse event terms and percentages. With no comparator and no reported efficacy estimate, the record supports description of study design and selected safety counts, but not a comparative treatment-effect conclusion.